Dennis Underwood

Dennis Underwood


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
YPYury Patskovsky
Yury Patskovsky
ANAswin Natarajan
Aswin Natarajan
LPLarysa Patskovska
Larysa Patskovska
SNSamantha Nyovanie
Samantha Nyovanie
BJBishnu Joshi
Bishnu Joshi
MKMichelle Krogsgaard
Michelle Krogsgaard
Altered protein phosphorylation in cancer cells often leads to surface presentation of phosphopeptide neoantigens. However, their role in cancer immunogenicity remains unclear. Here we describe a mechanism by which an HLA-B*0702-specific acute myeloid leukemia phosphoneoantigen, pMLL747–755(EPR(pS)PSHSM), is recognized by a cognate T cell receptor named TCR27, a candidate for cancer immunotherapy. We show that the replacement of phosphoserine P4with serine or phosphomimetics does not affect pMHC conformation or peptide-MHC affinity but abrogates TCR27-dependent T cell activation and weakens binding between TCR27 and pMHC. Here we describe the crystal structures for TCR27 and cognate pMHC, map of the interface produced by nuclear magnetic resonance, and a ternary complex generated using information-driven protein docking. Our data show that non-covalent interactions between the epitope phosphate group and TCR27 are crucial for TCR specificity. This study supports development of new treatment options for cancer patients through target expansion and TCR optimization.

28 July 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Ohanes Haroutoun AshekyanOhanes Haroutoun Ashekyan
Ohanes Haroutoun Ashekyan
NSNerses Shahbazyan
Nerses Shahbazyan
YBYeva Bareghamyan
Yeva Bareghamyan
AKAnna Kudryavzeva
Anna Kudryavzeva
DMDaria Mandel
Daria Mandel
Hans BinderHans Binder
Hans Binder
The molecular mechanisms of the liver metastasis of colorectal cancer (CRLM) remain poorly understood. Here, we applied machine learning and bioinformatics trajectory inference to analyze a gene expression dataset of CRLM. We studied the co-regulation patterns at the gene level, the potential paths of tumor development, their functional context, and their prognostic relevance. Our analysis confirmed the subtyping of five liver metastasis subtypes (LMS). We provide gene-marker signatures for each LMS, and a comprehensive functional characterization that considers both the hallmarks of cancer and the tumor microenvironment. The ordering of CRLMs along a pseudotime-tree revealed a continuous shift in expression programs, suggesting a developmental relationship between the subtypes. Notably, trajectory inference and personalized analysis discovered a range of epigenetic states that shape and guide metastasis progression. By constructing prognostic maps that divided the expression landscape into regions associated with favorable and unfavorable prognoses, we derived a prognostic expression score. This was associated with critical processes such as epithelial–mesenchymal transition, treatment resistance, and immune evasion. These factors were associated with responses to neoadjuvant treatment and the formation of an immuno-suppressive, mesenchymal state. Our machine learning-based molecular profiling provides an in-depth characterization of CRLM heterogeneity with possible implications for treatment and personalized diagnostics.

19 August 2021 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
ALAmanda M. Lulu
Amanda M. Lulu
KCKara L. Cummings
Kara L. Cummings
EJErin D. Jeffery
Erin D. Jeffery
PMPaisley T. Myers
Paisley T. Myers
DUDennis Underwood
Dennis Underwood
VEVictor H. Engelhard
Victor H. Engelhard
Elevated immunity to cancer-expressed antigens can be detected in people with no history of cancer and may contribute to cancer prevention. We have previously reported that MHC-restricted phosphopeptides are cancer-expressed antigens and targets of immune recognition. However, the extent to which this immunity reflects prior or ongoing phosphopeptide exposures was not investigated. In this study, we found that preexisting immune memory to cancer-expressed phosphopeptides was evident in most healthy donors, but the breadth among donors was highly variable. Although three phosphopeptides were recognized by most donors, suggesting exposures to common microbial/infectious agents, most of the 205 tested phosphopeptides were not recognized by peripheral blood mononuclear cells (PBMC) from any donor and the remainder were recognized by only 1 to 3 donors. In longitudinal analyses of 2 donors, effector immune response profiles suggested active reexposures to a subset of phosphopeptides. These findings suggest that the immunogens generating most phosphopeptide-specific immune memory are rare infectious agents or incipient cancer cells with distinct phosphoproteome dysregulations, and that repetitive immunogenic exposures occur in individual donors. Phosphopeptide-specific immunity in PBMCs and tumor-infiltrating lymphocytes from ovarian cancer patients was limited, regardless of whether the phosphopeptide was expressed on the tumor. However, 4 of 10 patients responded to 1 to 2 immunodominant phosphopeptides, and 1 showed an elevated effector response to a tumor-expressed phosphopeptide. As the tumors from these patients displayed many phosphopeptides, these data are consistent with lack of prior exposure or impaired ability to respond to some phosphopeptides and suggest that enhancing phosphopeptide-specific T-cell responses could be a useful approach to improve tumor immunotherapy.

1 December 2022 in Research Square
Verified
Preprint
Open access
PDF file
YPYury Patskovsky
Yury Patskovsky
ANAswin Natarajan
Aswin Natarajan
LPLarysa Patskovska
Larysa Patskovska
SNSamantha Nyovanie
Samantha Nyovanie
BJBishnu Joshi
Bishnu Joshi
MKMichelle Krogsgaard
Michelle Krogsgaard
Altered protein phosphorylation in cancer cells often leads to surface presentation of phosphopeptide neoantigens. However, their role in cancer immunogenicity remains unclear. Here we describe a mechanism by which an HLA-B*0702-specific acute myeloid leukemia phosphoneoantigen pMLL747-755(EPR(pS)PSHSM) is recognized by cognate TCR27, which is a candidate for immunotherapy of AML. We show that the replacement of phosphoserine P4with serine or phosphomimetics does not affect the pMHC conformation or peptide-MHC affinity but abrogates the TCR27-dependent T cell activation and weakens binding between TCR27 and pMHC. We determined the crystal structures for TCR27 and cognate pMHC, mapped the pMHC-TCR interface by TROSY-NMR, generated a ternary pMHC-TCR complex using information-driven protein docking, and identified key polar interactions between phosphate group at P4and TCR27 that are crucial for ternary complex stability and TCR27 specificity. These data will support development of cancer immunotherapy through target expansion and TCR optimization. *The authors would like to note that Yury Patskovsky and Aswin Natarajan contributed equally.

27 July 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
YPYury Patskovsky
Yury Patskovsky
ANAswin Natarajan
Aswin Natarajan
LPLarysa Patskovska
Larysa Patskovska
SNSamantha Nyovanie
Samantha Nyovanie
BJBishnu Joshi
Bishnu Joshi
MKMichelle Krogsgaard
Michelle Krogsgaard